INTRODUCTION
Sickle cell disease (SCD) results from a mutation in the beta-globin gene of haemoglobin (Hb) and is one of the most common inherited diseases worldwide (1) . Although most common among people of African descent, it is seen in many other populations due to population migration (1) (2) (3) . In the United States of America (USA), which has universal newborn SCD screening, SCD is identified in one out of every 375 AfricanAmerican infants (4). However, many countries in the Caribbean have a higher estimated birth prevalence of SCD and yet, do not have universal newborn screening programmes for SCD. For example, Jamaica has demonstrated a birth prevalence of SCD as high as 1:150 births with a limited newborn screening programme (5) . Newborn screening for SCD allows for early diagnosis and the opportunity to initiate early preventative treatment. Universal newborn screening for SCD was initiated in the USA after the pivotal prophylactic penicillin study (PROPS) demonstrated reduced infections and a subsequent reduction in mortality (6) . Newborn screening, coupled with a paediatric comprehensive care programme, has been shown to decrease early childhood mortality as well as disease morbidity not only in the USA, but also in other worldwide populations (5, (7) (8) (9) .
St Vincent and the Grenadines (SVG) is a nation that comprises an archipelago of islands with a total population of approximately 110 000 and approximately 1700 births per year (10) . There are no newborn screening programmes in SVG.
There are no published data on the prevalence or birth prevalence of SCD in SVG. The objective of this study was to obtain birth prevalence estimates for SCD in SVG using the local available data in order to assess whether a pilot newborn screening programme should be conducted in this population. For the results that were positive for SCD, the patients' date of birth (DOB), age at time of test and test results were extracted. It was anticipated that there would be patients for whom a DOB was not recorded; therefore, it was decided a priori that the DOB would be extrapolated for those patients based on their age at the time of the test. Extrapolated DOBs were calculated as if the patient was at the exact age given at the time of the test. For the patients who were ≥ 1 year of age at the time of the test, the DOB was calculated as if the child was exactly x years and zero month old. Therefore, the DOB was estimated by assigning the test result day and month as the patient's birth day and month. For patients who were < 1 year of age, the DOB was calculated as if the child was x months and zero day old at the time of the test. To ensure that the patients were not counted twice, we included the initial test results and excluded subsequent tests for the patients with the same name and DOB. However, for patients where the DOB was extrapolated, we excluded repeat tests for the patients with the same name, gender and result, if the year of birth was the same. The patients with no demographic information documented were excluded from our analysis.
SUBJECTS AND METHODS
In the absence of a universal newborn screening programme, it was expected that the patients would be diagnosed symptomatically and at later ages. Studies of the clinical presentation of SCD showed that disease-specific symptoms were seen in 96% of the patients with HbSS by the age of eight years, but were seen in only about 75% of the patients with HbSC by the age of eight years (11, 12) . Based on this information and the available Hb electrophoresis data, the estimation of the SCD birth prevalence for those patients born in 2006 and 2007 was chosen. These patients would be the oldest patients in the data set and would allow for the inclusion of patients with a late diagnosis, thereby improving the accuracy of our estimates.
The 
RESULTS
In this study, there were 21 children who were born between January 1, 2006 and December 31, 2007 and had positive results for SCD ie were diagnosed with SCD during the study period (Fig. 1 ). Of those with SCD, 67% (14/21) were diagnosed with homozygous SS disease and 33% (7/21) with SC disease. The earliest age at diagnosis was at eight months of age, and 86% (18/21) of the patients were diagnosed at one year of age or older. 
DISCUSSION
It was estimated from this study that for the years 2006 and 2007, 1:172 Vincentian newborns were diagnosed with SCD. In addition, the results showed that there were significant delays in the diagnosis as the majority of the patients were diagnosed over the age of one year, which is older than is recommended. A delayed diagnosis results in deferred initiation of penicillin prophylaxis which increases morbidity and mortality (13) .
The estimated 1:172 Vincentian newborns with SCD was within the expected range based on similar reports from other nations in the Caribbean. Published data from geographically-related regions where limited or universal newborn screening for SCD exists estimated ratios for birth prevalence as high as 1:150 in Jamaica, 1:173 in Haiti and 1:304 in Guadeloupe. These were all higher than the 1:375 for African Americans in the USA (4, 5, 8, 14) . These estimates were limited by the extrapolation of DOB, the use of handwritten records and our lack of mortality records. For the patients included in the analysis, only 9.5% (2 of the 21 patients) had a documented DOB, and therefore the DOB was extrapolated in most cases. In addition, the lack of mortality data would likely influence the results of this study in estimating the true birth prevalence of SCD. It is well known that SCD is associated with early childhood mortality (9) . With no access to mortality data, it was possible that young patients had died prior to undergoing testing or diagnosis and were not included in the counts. Furthermore, it is possible that there might have been patients diagnosed at later ages outside of the study period which might also lead to an underestimation of birth prevalence estimates.
In the absence of a newborn screening programme or a population-based surveillance system, a cross-sectional approach using existing data was the only option to estimate birth prevalence. Fortunately, this study had a single source of data, the central laboratory at the MCMH which is the only laboratory in SVG capable of diagnosing SCD. This precluded missing additional persons which is possible when using hospital utilization data which might be biased to a sicker population and miss counting healthier persons (15) . This was a strength as the counts were all confirmed SCD cases. This singular source of data also decreased the chance of missing data because the patients were diagnosed from testing at this laboratory.
Despite the significant morbidity and mortality caused by SCD, the improvements in early diagnosis and management have significantly improved outcomes. Key enhancements include early initiation of prophylactic penicillin, pneumococcal immunization, parental education and close monitoring (5, 6, 16, 17) . Data from regions of Sub-Saharan Africa have shown that patients are at a 50% risk of death prior to five years of age if not diagnosed and managed appropriately (18, 19) . These data confirmed the need for newborn screening to avoid preventable early mortality and morbidity. In 2006, the World Health Organization stated that analyses of the treatments for haemoglobin disorders had demonstrated that specialized centres and newborn screening programmes were cost-effective approaches to improving outcomes for SCD and thalassaemia (19) . Therefore, in developing nations where the burden of the disease is high, universal newborn screening along with comprehensive care is needed (20) .
This study was the first to determine estimates for the birth prevalence of SCD among newborns in SVG and thus contributes to the emerging data on the birth prevalence of SCD in the Caribbean. The estimates were similar to those of the other countries in the region, all of which were higher than those of the USA where universal newborn screening for SCD exists. Despite the contributions made to the field of SCD by the work done in Jamaica, the Caribbean continues to lag behind in the implementation of newborn screening programmes for SCD (21, 22) . Given the relatively high estimated numbers of Vincentian newborns affected by SCD and the delays in their diagnosis, there is the need to pilot a universal newborn screening programme. This would give more accurate birth prevalence estimates and determine the feasibility and cost effectiveness of a newborn screening programme in this population.
